Literature DB >> 19810167

The in-vitro activity of ceftazidime against clinically important pathogens.

H Knothe1, G A Dette.   

Abstract

A total of 1414 strains of Gram-negative bacilli and 250 strains of Gram-positive cocci were tested for antimicrobial susceptibility using the broth dilution method. The strains were clinical isolates from 26 hospitals in the Rhein-Main area. All the strains were tested against ceftazidime and ten other cephalosporin antibiotics. Ceftazidime was found to exhibit an in-vitro activity against Enterobacteriaceae similar to that of cefotaxime, moxalactam and other new members of the cephalosporin class, but was more active against Acinetobacter species. Ceftazidime shows extremely high activity both against carbenicillin-sensitive and -resistant strains of Pseudomonas aeruginosa. Similarly, ampicillin-sensitive and -resistant strains of Haemophilus influenzae are susceptible to ceftazidime. The activity of ceftazidime against Staphylococcus aureus is limited and, like other cephalosporins, it is inactive against Streptococcus faecalis.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 19810167     DOI: 10.1093/jac/8.suppl_b.33

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  16 in total

1.  Multicenter study of the sensitivity of Pseudomonas aeruginosa to antimicrobial agents.

Authors:  B Wiedemann; K Machka; R Malottke
Journal:  Eur J Clin Microbiol       Date:  1985-04       Impact factor: 3.267

Review 2.  In vitro antibacterial effects of cephalosporins.

Authors:  J D Williams; F Moosdeen
Journal:  Drugs       Date:  1987       Impact factor: 9.546

3.  [Rational parameters in the treatment of bacterial meningitis with modern cephalosporins].

Authors:  O Brückner; M Trautmann
Journal:  Infection       Date:  1987       Impact factor: 3.553

Review 4.  [Possibilities for the use of basic cephalosporins].

Authors:  A C Rodloff; H Knothe
Journal:  Infection       Date:  1993       Impact factor: 3.553

5.  [Ceftazidime versus cefotaxime in the therapy of severe infections in intensive care patients].

Authors:  E Müller; J Heinkelein
Journal:  Infection       Date:  1987       Impact factor: 3.553

6.  [Clinical and bacteriologic effectiveness of ceftazidime in infections with gram-positive pathogens].

Authors:  R Tolxdorff-Neutzling; G Klages; H Danner
Journal:  Infection       Date:  1987       Impact factor: 3.553

Review 7.  Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  D M Richards; R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

8.  Antistaphylococcal antibodies in cystic fibrosis.

Authors:  B Strandvik; A Hollsing; R Möllby; M Granström
Journal:  Infection       Date:  1990 May-Jun       Impact factor: 3.553

9.  Ceftazidime, ceftizoxime, cefotaxime and HR 221 in experimental chronic Escherichia coli pyelonephritis in rats.

Authors:  R Marre; D Herhahn; E Schulz; H Freiesleben; K Sack
Journal:  Infection       Date:  1983       Impact factor: 3.553

10.  The effect of N-formimidoyl thienamycin, ceftazidime, cefotiam, ceftriaxone and cefotaxime on non-fermentative Gram-negative rods, Aeromonas, Plesiomonas and Enterobacter agglomerans.

Authors:  A von Graevenitz; C Bucher
Journal:  Infection       Date:  1982 Sep-Oct       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.